Prestige Biopharma Limited

PRESTIGE BIOPHARMA (PBP) is an innovative biopharma company specializing in developing and manufacturing innovative antibody-based drugs and biosimilars. Its trastuzumab biosimilar, Tuznue, received EU approval in September 2024, and its innovative pipeline includes a monoclonal antibody targeting pancreatic cancer in clinical trials and a solid-tumor-targeted monoclonal antibody in preclinical development, backed by a robust biosimilar portfolio targeting the next wave of patent expiries, with the company open to partnerships and collaborations.